{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:18:36Z","timestamp":1793157516106,"version":"4.5.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["320030L_189369"],"award-info":[{"award-number":["320030L_189369"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I-4565"],"award-info":[{"award-number":["I-4565"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.canlet.2022.01.015","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:07:21Z","timestamp":1642417641000},"page":"156-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"special_numbering":"C","title":["Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer"],"prefix":"10.1016","volume":"530","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-0040","authenticated-orcid":false,"given":"Juening","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-8395","authenticated-orcid":false,"given":"Federico","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3609-5956","authenticated-orcid":false,"given":"Francesco","family":"Bonollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mingels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afshar-Oromieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1716-5237","authenticated-orcid":false,"given":"Sofia","family":"Karkampouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.canlet.2022.01.015_bib1","first-page":"7","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2022.01.015_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2967\/jnumed.119.234914","article-title":"18)F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy","volume":"61","author":"Eiber","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Canc."},{"key":"10.1016\/j.canlet.2022.01.015_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev."},{"issue":"2020","key":"10.1016\/j.canlet.2022.01.015_bib5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity \u2014 United States, 2001\u20132017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.canlet.2022.01.015_bib6","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2022.01.015_bib7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib9","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1002\/cam4.1697","article-title":"Clinical landscape of cancer metastases","volume":"7","author":"Riihim\u00e4ki","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncr.30336","article-title":"Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and\/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial","volume":"123","author":"Loriot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.11522","article-title":"Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience","volume":"98","author":"Tremont-Lukats","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib13","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.wneu.2020.02.152","article-title":"Prostate cancer brain metastases: a single-institution experience","volume":"138","author":"Bhambhvani","year":"2020","journal-title":"World Neurosurg."},{"key":"10.1016\/j.canlet.2022.01.015_bib14","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Onco Rev."},{"key":"10.1016\/j.canlet.2022.01.015_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2022.01.015_bib17","first-page":"3935","article-title":"Role of tumor-derived exosomes in bone metastasis","volume":"18","author":"Li","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2022.01.015_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/JU.0000000000000137","article-title":"Bringing prostate cancer germline genetics into clinical practice","volume":"202","author":"Das","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib19","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2011.35.1916","article-title":"Common gene rearrangements in prostate cancer","volume":"29","author":"Rubin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2022.01.015_bib21","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib22","series-title":"Beyond the Androgen Receptor: Targeting Actionable Drivers of Prostate Cancer","first-page":"1","author":"Nelson","year":"2017"},{"key":"10.1016\/j.canlet.2022.01.015_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib24","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.01.015_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2301","article-title":"Traversing the genomic landscape of prostate cancer from diagnosis to death","volume":"44","author":"Hieronymus","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2022.01.015_bib27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.01.015_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.01.015_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.01.015_bib30","series-title":"Prospective Genomic Profiling of Prostate Cancer across Disease States Reveals Germline and Somatic Alterations that May Affect Clinical Decision Making","first-page":"2017","author":"Abida","year":"2017"},{"key":"10.1016\/j.canlet.2022.01.015_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib32","doi-asserted-by":"crossref","first-page":"11390","DOI":"10.1073\/pnas.1902645116","article-title":"Aneuploidy drives lethal progression in prostate cancer","volume":"116","author":"Stopsack","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2022.01.015_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37294","article-title":"Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death","volume":"7","author":"Hieronymus","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.canlet.2022.01.015_bib34","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1073\/pnas.1411446111","article-title":"Copy number alteration burdeInt. J. Endocr. Oncol.n predicts prostate cancer relapse","volume":"111","author":"Hieronymus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2022.01.015_bib35","article-title":"Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines","volume":"6","author":"Clermont","year":"2019","journal-title":"Int. J. Endocr. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2022.01.015_bib37","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","article-title":"N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"129","author":"Berger","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.01.015_bib38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/pros.23831","article-title":"PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma)","volume":"79","author":"Shah","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib39","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.18632\/oncotarget.6955","article-title":"PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist\/radiation combination therapy","volume":"7","author":"Armstrong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.01.015_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.01.015_bib41","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-21-0121","article-title":"A subset of localized prostate cancer displays an immunogenic phenotype Associated with losses of key tumor suppressor genes","volume":"27","author":"Calagua","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib42","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.18632\/oncotarget.14399","article-title":"TMPRSS2-ERG fusion promotes prostate cancer metastases in bone","volume":"8","author":"Deplus","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.01.015_bib43","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41388-018-0575-7","article-title":"Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.01.015_bib44","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1038\/s41598-017-05209-z","article-title":"Identification of FBXL4 as a metastasis associated gene in prostate cancer","volume":"7","author":"Stankiewicz","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2022.01.015_bib45","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","article-title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","volume":"10","author":"van Dessel","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.01.015_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.canlet.2015.12.022","article-title":"Regulation of prostate cancer progression by the tumor microenvironment","volume":"380","author":"Shiao","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2022.01.015_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071887","article-title":"The role of cancer-associated fibroblasts in prostate cancer tumorigenesis","volume":"12","author":"Bonollo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2022.01.015_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.seminoncol.2014.03.004","article-title":"Tumor microenvironment and metabolism in prostate cancer","volume":"41","author":"Chiarugi","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib51","first-page":"2912","article-title":"Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling","volume":"8","author":"Tuxhorn","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib52","first-page":"5002","article-title":"Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium","volume":"59","author":"Olumi","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.eururo.2009.08.026","article-title":"Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells","volume":"58","author":"Thalmann","year":"2010","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/path.1427","article-title":"The myofibroblast in wound healing and fibrocontractive diseases","volume":"200","author":"Gabbiani","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2022.01.015_bib55","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030510","article-title":"Cellular constituents of the prostate stroma: key contributors to prostate cancer progression and therapy resistance","volume":"8","author":"Levesque","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib56","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/ijms19051532","article-title":"Fibroblasts in the tumor microenvironment: shield or spear?","volume":"19","author":"Alkasalias","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2022.01.015_bib57","first-page":"39","article-title":"Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer","volume":"10","author":"Yang","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.canlet.2022.01.015_bib58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2022.01.015_bib59","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrc743","article-title":"Oncogenic resistance to growth-limiting conditions","volume":"2","author":"Blagosklonny","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.tig.2008.10.012","article-title":"Co-evolution of tumor cells and their microenvironment","volume":"25","author":"Polyak","year":"2009","journal-title":"Trends Genet."},{"key":"10.1016\/j.canlet.2022.01.015_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcdb.2009.11.016","article-title":"Tumor-stroma co-evolution in prostate cancer progression and metastasis","volume":"21","author":"Josson","year":"2010","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2022.01.015_bib62","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1158\/0008-5472.CAN-08-2492","article-title":"Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis","volume":"68","author":"Sung","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-030-32656-2_9","article-title":"The bone microenvironment in prostate cancer metastasis","volume":"1210","author":"DiNatale","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2022.01.015_bib64","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fphar.2020.00757","article-title":"The bone extracellular matrix in bone formation and regeneration","volume":"11","author":"Lin","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2022.01.015_bib65","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3389\/fonc.2019.01376","article-title":"The extracellular, cellular, and nuclear stiffness, a trinity in the cancer resistome-a review","volume":"9","author":"Deville","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib66","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fonc.2019.00924","article-title":"Identification of SPP1 as an extracellular matrix signature for metastatic castration-resistant prostate cancer","volume":"9","author":"Pang","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib67","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.2147\/OTT.S258252","article-title":"Role of \u03b1V\u03b23 in prostate cancer: metastasis initiator and important therapeutic target","volume":"13","author":"Tang","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2022.01.015_bib68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1593\/neo.08380","article-title":"Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase","volume":"10","author":"Hall","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2022.01.015_bib69","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/0008-5472.CAN-17-0064","article-title":"Tenascin-C and integrin \u03b19 mediate interactions of prostate cancer with the bone microenvironment","volume":"77","author":"San Martin","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/19336918.2015.1008332","article-title":"Tenascin-C and integrins in cancer","volume":"9","author":"Yoshida","year":"2015","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.canlet.2022.01.015_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123786","article-title":"Stroma transcriptomic and proteomic profile of prostate cancer metastasis xenograft models reveals prognostic value of stroma signatures","volume":"12","author":"Karkampouna","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2022.01.015_bib72","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1476-4598-11-66","article-title":"Integrin \u03b1v\u03b23 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2\/Smad 5\/receptor activator of NF-\u03baB ligand signaling axis","volume":"11","author":"Gupta","year":"2012","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib73","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib74","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1038\/s41598-018-25435-3","article-title":"Matrilysin\/MMP-7 cleavage of perlecan\/HSPG2 complexed with semaphorin 3A supports FAK-mediated stromal invasion by prostate cancer cells","volume":"8","author":"Grindel","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2022.01.015_bib75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41585-018-0020-2","article-title":"Translational models of prostate cancer bone metastasis","volume":"15","author":"Berish","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib76","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jbmr.3618","article-title":"Understanding the bone in cancer metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib77","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2012.2","article-title":"Role of denosumab in prostate cancer","volume":"15","author":"Helo","year":"2012","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2022.01.015_bib78","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrell","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib79","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fonc.2014.00364","article-title":"The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis","volume":"4","author":"Ganguly","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib81","doi-asserted-by":"crossref","DOI":"10.1007\/s12018-013-9144-3","article-title":"Solid tumours show osteotropism: mechanisms of bone metastases","volume":"11","author":"Roato","year":"2013","journal-title":"Clin. Rev. Bone Miner. Metabol."},{"key":"10.1016\/j.canlet.2022.01.015_bib82","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.canlet.2022.01.015_bib83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.trecan.2020.09.006","article-title":"Emerging players in prostate cancer\u2013bone niche communication","volume":"7","author":"Furesi","year":"2021","journal-title":"Trends Canc."},{"key":"10.1016\/j.canlet.2022.01.015_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb9265","article-title":"Human and mouse bones physiologically integrate in a humanized mouse model while maintaining species-specific ultrastructure","volume":"6","author":"Moreno-Jim\u00e9nez","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2022.01.015_bib85","series-title":"Human, Mouse, and Dog Bone Marrow Show Similar Mesenchymal Stromal Cells within a Distinctive Microenvironment","author":"Meza-Le\u00f3n","year":"2021"},{"key":"10.1016\/j.canlet.2022.01.015_bib86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrc1528","article-title":"Osteoblasts in prostate cancer metastasis to bone","volume":"5","author":"Logothetis","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib88","first-page":"124","article-title":"The role of osteoblasts in bone metastasis","volume":"5","author":"Ottewell","year":"2016","journal-title":"J. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114530","article-title":"The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches","volume":"9","author":"\u00d6zdemir","year":"2014","journal-title":"PLoS One"},{"issue":"No 48","key":"10.1016\/j.canlet.2022.01.015_bib90","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25608","article-title":"Osteolytic cancer cells induce vascular\/axon guidance processes in the bone\/bone marrow stroma","volume":"9","author":"Hensel","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.01.015_bib91","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.2910210305","article-title":"Isolation of a human prostate carcinoma cell line (DU 145)","volume":"21","author":"Stone","year":"1978","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib92","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1128\/MCB.00955-07","article-title":"Activation of the RalGEF\/Ral pathway promotes prostate cancer metastasis to bone","volume":"27","author":"Yin","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2022.01.015_bib93","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2018.00222","article-title":"Extracellular vesicles in prostate cancer carcinogenesis, diagnosis, and management","volume":"8","author":"Vlaeminck-Guillem","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062118","article-title":"Exosomes in prostate cancer diagnosis, prognosis and therapy","volume":"21","author":"Lorenc","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2022.01.015_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124449","article-title":"Cytokines and chemokines as mediators of prostate cancer metastasis","volume":"21","author":"Adekoya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2022.01.015_bib96","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1210\/endo.138.9.5364","article-title":"Activation of the Janus kinase\/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation","volume":"138","author":"Bellido","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2022.01.015_bib97","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","article-title":"Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism","volume":"65","author":"Dai","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib98","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jcb.20735","article-title":"Role of Wnts in prostate cancer bone metastases","volume":"97","author":"Hall","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2022.01.015_bib99","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pros.23929","article-title":"Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment","volume":"80","author":"Vickman","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib100","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1158\/0008-5472.CAN-07-1286","article-title":"Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo","volume":"67","author":"Loberg","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib101","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1593\/neo.06280","article-title":"CCL2 is a potent regulator of prostate cancer cell migration and proliferation","volume":"8","author":"Loberg","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2022.01.015_bib102","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41388-018-0540-5","article-title":"Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis","volume":"38","author":"Probert","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.01.015_bib103","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/iju.13145","article-title":"Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression","volume":"23","author":"Liu","year":"2016","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib104","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1073\/pnas.1717363115","article-title":"Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A","volume":"115","author":"Hashimoto","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2022.01.015_bib105","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1096\/fj.14-261404","article-title":"Proteomic signatures of extracellular vesicles secreted by nonmineralizing and mineralizing human osteoblasts and stimulation of tumor cell growth","volume":"29","author":"Morhayim","year":"2015","journal-title":"Faseb. J."},{"key":"10.1016\/j.canlet.2022.01.015_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12042","article-title":"Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner","volume":"10","author":"Henrich","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.canlet.2022.01.015_bib107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.01.015_bib108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mc.23157","article-title":"Exosomes secreted by prostate cancer cells under hypoxia promote matrix metalloproteinases activity at pre-metastatic niches","volume":"59","author":"Deep","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2022.01.015_bib109","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1084\/jem.20190158","article-title":"Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis","volume":"216","author":"Dai","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib110","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1074\/jbc.M308158200","article-title":"Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines","volume":"279","author":"Zayzafoon","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2022.01.015_bib111","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41467-017-00460-4","article-title":"Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer","volume":"8","author":"Tyekucheva","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.01.015_bib112","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/pros.20988","article-title":"The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma","volume":"69","author":"Tsunoda","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib113","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.ajpath.2014.06.022","article-title":"Stromal androgen receptor in prostate development and cancer","volume":"184","author":"Singh","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2022.01.015_bib114","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pros.20927","article-title":"Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients","volume":"69","author":"Wikstr\u00f6m","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/pros.20154","article-title":"Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease","volume":"63","author":"Ricciardelli","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib116","doi-asserted-by":"crossref","first-page":"16135","DOI":"10.18632\/oncotarget.3873","article-title":"Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome","volume":"6","author":"Leach","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.01.015_bib117","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W","article-title":"Localization of androgen receptor expression in human bone marrow","volume":"193","author":"Mantalaris","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2022.01.015_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244663","article-title":"The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients","volume":"15","author":"Gevaert","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2022.01.015_bib119","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-019-02185-y","article-title":"Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer","volume":"18","author":"Kiebish","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/jcm7040068","article-title":"Role of stromal paracrine signals in proliferative diseases of the aging human prostate","volume":"7","author":"Ishii","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib121","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41374-019-0352-4","article-title":"Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure","volume":"100","author":"Kajiwara","year":"2020","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2022.01.015_bib122","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","article-title":"Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer","volume":"38","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib123","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/1878-0261.12327","article-title":"Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration","volume":"12","author":"Cioni","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib124","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-07-6289","article-title":"Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity","volume":"68","author":"Placencio","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/ERC-14-0199","article-title":"Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone","volume":"21","author":"Ottewell","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib126","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","article-title":"Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo","volume":"65","author":"van der Pluijm","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib127","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","article-title":"Transcriptional mediators of treatment resistance in lethal prostate cancer","volume":"27","author":"He","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib128","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2890","article-title":"Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B","volume":"18","author":"Sun","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib129","first-page":"4096","article-title":"Metastatic prostate cancer in a transgenic mouse","volume":"56","author":"Gingrich","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/pros.10215","article-title":"Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model","volume":"55","author":"Kaplan-Lefko","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2022.01.015_bib131","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1073\/pnas.95.26.15382","article-title":"A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells","volume":"95","author":"Garabedian","year":"1998","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2022.01.015_bib132","first-page":"2239","article-title":"A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential","volume":"61","author":"Masumori","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib133","first-page":"900","article-title":"Prostate cancer progression, metastasis, and gene expression in transgenic mice","volume":"57","author":"Perez-Stable","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib134","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.humpath.2007.04.008","article-title":"Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy","volume":"38","author":"Yanagisawa","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2022.01.015_bib135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nm.4463","article-title":"Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms","volume":"24","author":"Bezzi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib136","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib137","first-page":"1082","article-title":"A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance","volume":"1","author":"Arriaga","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.canlet.2022.01.015_bib138","doi-asserted-by":"crossref","first-page":"E3506","DOI":"10.1073\/pnas.1303558110","article-title":"ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer","volume":"110","author":"Aytes","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.canlet.2022.01.015_bib139","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030528","article-title":"Genetically engineered mouse models of prostate cancer in the postgenomic era","volume":"9","author":"Arriaga","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2012.01.039","article-title":"Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases","volume":"148","author":"Ding","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib141","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1158\/0008-5472.CAN-12-4213","article-title":"Animal models of human prostate cancer: the consensus report of the New York meeting of the mouse models of human cancers consortium prostate pathology committee","volume":"73","author":"Ittmann","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib142","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature09677","article-title":"SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression","volume":"470","author":"Ding","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.01.015_bib143","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ng.2650","article-title":"A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer","volume":"45","author":"Lunardi","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2022.01.015_bib144","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/onc.2011.236","article-title":"A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53","volume":"31","author":"Kim","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.01.015_bib145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1535-6108(03)00197-1","article-title":"Myc-driven murine prostate cancer shares molecular features with human prostate tumors","volume":"4","author":"Ellwood-Yen","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.01.015_bib146","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.18632\/oncotarget.27317","article-title":"A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host","volume":"10","author":"Simons","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.01.015_bib147","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-14-3280","article-title":"Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer","volume":"76","author":"Hubbard","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib148","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2022.01.015_bib149","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jsb.2010.11.014","article-title":"The organization of the osteocyte network mirrors the extracellular matrix orientation in bone","volume":"173","author":"Kerschnitzki","year":"2011","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.canlet.2022.01.015_bib150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nprot.2017.002","article-title":"Engineering a humanized bone organ model in mice to study bone metastases","volume":"12","author":"Martine","year":"2017","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2022.01.015_bib151","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s42003-021-02527-x","article-title":"A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells","author":"McGovern","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2022.01.015_bib152","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg2564","article-title":"In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer","volume":"7","author":"Bock","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2022.01.015_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110438","article-title":"Humanization of the prostate microenvironment reduces homing of PC3 prostate cancer cells to human tissue-engineered bone","volume":"10","author":"McGovern","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2022.01.015_bib154","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib155","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1158\/0008-5472.CAN-12-0820","article-title":"B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib156","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","author":"Kane","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.canlet.2022.01.015_bib157","first-page":"1369","article-title":"A combined PET\/CT scanner for clinical oncology","volume":"41","author":"Beyer","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib158","first-page":"990","article-title":"PET imaging of prostate cancer using carbon-11-choline","volume":"39","author":"Hara","year":"1998","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib159","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3162","article-title":"Choline metabolism in malignant transformation","volume":"11","author":"Glunde","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I","volume":"205","author":"Lowrance William","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib161","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1148\/rg.345130061","article-title":"Newer PET application with an old tracer: role of 18F-NaF skeletal PET\/CT in oncologic practice","volume":"34","author":"Bastawrous","year":"2014","journal-title":"Radiographics"},{"key":"10.1016\/j.canlet.2022.01.015_bib162","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00259-018-4048-6","article-title":"Comparison of [68Ga]Ga-PSMA-11 PET\/CT with [18F]NaF PET\/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy","volume":"45","author":"Uprimny","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"5B","key":"10.1016\/j.canlet.2022.01.015_bib163","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib164","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib165","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.01.015_bib166","unstructured":"K.A.-O. Rahbar, A. Afshar-Oromieh, H. Jadvar, H. Ahmadzadehfar, PSMA Theranostics: Current Status and Future Directions."},{"key":"10.1016\/j.canlet.2022.01.015_bib167","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib168","series-title":"The Oncogenomics Handbook","author":"Shimkets","year":"2005"},{"key":"10.1016\/j.canlet.2022.01.015_bib169","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000001349","article-title":"68Ga-PSMA-11 dynamic PET\/CT imaging in primary prostate cancer","volume":"41","author":"Sachpekidis","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib170","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2022.01.015_bib171","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib172","first-page":"1","article-title":"PSMA-negative prostate cancer and the continued value of choline-PET\/CT, Nuklearmedizin","volume":"59","author":"Alberts","year":"2020","journal-title":"Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib173","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68)Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib174","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00259-017-3858-2","article-title":"68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making","volume":"45","author":"Grubmuller","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12885-018-5200-1","article-title":"Randomized prospective phase III trial of (68)Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]","volume":"19","author":"Calais","year":"2019","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2022.01.015_bib176","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib177","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00259-018-4204-z","article-title":"Why should we be concerned about a \u201cg\u201d","volume":"46","author":"Frangos","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib178","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib179","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib180","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S1470-2045(18)30604-1","article-title":"Consensus on molecular imaging and theranostics in prostate cancer","volume":"19","author":"Fanti","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib181","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00774-013-0507-0","article-title":"Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain","volume":"32","author":"Gallicchio","year":"2014","journal-title":"J. Bone Miner. Metabol."},{"key":"10.1016\/j.canlet.2022.01.015_bib182","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose\u2013response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2022.01.015_bib183","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib184","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2022.01.015_bib185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2022.01.015_bib186","first-page":"e6806","article-title":"A single-center retrospective analysis of the effect of radium-223 (Xofigo) on pancytopenia in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Skelton","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.canlet.2022.01.015_bib187","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-017-3665-9","article-title":"Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.canlet.2022.01.015_bib188","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2022.01.015_bib189","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2022.01.015_bib190","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2022.01.015_bib191","author":"US National Library of Medicine"},{"key":"10.1016\/j.canlet.2022.01.015_bib192","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2022.01.015_bib193","author":"US National Library of Medicine"},{"key":"10.1016\/j.canlet.2022.01.015_bib194","doi-asserted-by":"crossref","first-page":"36520","DOI":"10.1038\/srep36520","article-title":"Axl is required for TGF-\u03b22-induced dormancy of prostate cancer cells in the bone marrow","volume":"6","author":"Yumoto","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2022.01.015_bib195","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-017-0365-1","article-title":"Osteomimicry: how the seed grows in the soil","author":"Rucci","year":"2018","journal-title":"Calcif. Tissue Int."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:04:43Z","timestamp":1777550683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":193,"alternative-id":["S0304383522000234"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.01.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}